GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibikase Therapeutics Inc (NAS:IKT) » Definitions » 6-1 Month Momentum %

IKT (Inhibikase Therapeutics) 6-1 Month Momentum % : 74.60% (As of Apr. 07, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Inhibikase Therapeutics 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2025-04-07), Inhibikase Therapeutics's 6-1 Month Momentum % is 74.60%.

The industry rank for Inhibikase Therapeutics's 6-1 Month Momentum % or its related term are showing as below:

IKT's 6-1 Month Momentum % is ranked better than
94.57% of 1473 companies
in the Biotechnology industry
Industry Median: -13.4 vs IKT: 74.60

Competitive Comparison of Inhibikase Therapeutics's 6-1 Month Momentum %

For the Biotechnology subindustry, Inhibikase Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inhibikase Therapeutics's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Inhibikase Therapeutics's 6-1 Month Momentum % falls into.


;
;

Inhibikase Therapeutics  (NAS:IKT) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inhibikase Therapeutics  (NAS:IKT) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Inhibikase Therapeutics 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Inhibikase Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Inhibikase Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
3350 Riverwood Parkway SE, Suite 1900, Atlanta, GA, USA, 30339
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Executives
Paul C Grint director 7757 DOUGHILL COURT, SAN DIEGO CA 92127
Dennis N Berman director 9605 SCRANTON RD, STE 240, SAN DIEGO CA 92121
Roy Lester Freeman director 256 SUMMIT AVE, BROOKLINE MA 02446
Gisele Dion director C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Milton H. Werner director, 10 percent owner, officer: President and CEO 3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA GA 30339
Joseph Frattaroli officer: Cheif Financial Officer
Elizabeth G. O'farrell director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Daniel Kalman 10 percent owner 3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA GA 30339